Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations
Open Access
- 17 October 2025
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (1)
Abstract
Classic and hybrid pharmacometric‐machine learning models (hPMxML) are gaining momentum for applications in clinical drug development and precision medicine, especially within the oncology therapeutic area. However, standardized workflows are needed to ensure transparency, rigor, and effective communication for broader adoption. In this tutorial, we review pharmacometric (PMx) and machine learning (ML) reporting standards and evaluate them against hPMxML works in oncology contexts as a motivational example to identify current deficiencies and propose mitigation strategies for future efforts. The revealed gaps include insufficient benchmarking, absence of error propagation, feature stability assessments, and ablation studies, limited focus on external validation and final parametrization, and discrepancies between the performance metrics chosen and the original clinical questions. To address these, we propose a checklist for hPMxML model development and reporting, consisting of steps for estimand definition, data curation, covariate selection, hyperparameter tuning, convergence assessment, model explainability, diagnostics, uncertainty quantification, validation and verification with sensitivity analyses. This standardized approach is expected to enhance the reliability and reproducibility of hPMxML outputs, enabling their confident application in oncology clinical drug development, while fostering trust among all stakeholders.Keywords
Funding Information
- Roche
This publication has 70 references indexed in Scilit:
- Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic BiomarkersClinical Pharmacology & Therapeutics, 2024
- Applying Neural ODEs to Derive a Mechanism‐Based Model for Characterizing Maturation‐Related Serum Creatinine Dynamics in Preterm NewbornsThe Journal of Clinical Pharmacology, 2024
- Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use AuthorizationClinical Pharmacology & Therapeutics, 2024
- Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic OutcomesClinical Pharmacology & Therapeutics, 2024
- Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision MedicineClinical Pharmacology & Therapeutics, 2024
- Current Status and Future Directions: The Application of Artificial Intelligence/Machine Learning for Precision MedicineClinical Pharmacology & Therapeutics, 2024
- Machine Learning‐Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical TrialsClinical Pharmacology & Therapeutics, 2023
- Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best PracticesClinical Pharmacology & Therapeutics, 2023
- Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021Clinical Pharmacology & Therapeutics, 2022
- Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapyCPT: Pharmacometrics & Systems Pharmacology, 2021